International comparison of drug consumption: Impact of prices

The Determinants of Life Expectancy: An Analysis of the OECD Health Data

“…dollars using GDP PPP exchange rates underestimate actual pharmaceutical expenditures outside the United States. The drug-specific PPP exchange rates yield results that are consistent with those obtained using more accurate conversion factors developed by Szuba (1986) and others. Unfonunately.…”

The Determinants of Life Expectancy: An Analysis of the OECD Health Data

“…dollars using GDP PPP exchange rates underestimate actual pharmaceutical expenditures outside the United States. The drug-specific PPP exchange rates yield results that are consistent with those obtained using more accurate conversion factors developed by Szuba (1986) and others. Unfonunately.…”

Is the United States an outlier in health care and health outcomes? A preliminary analysis

“…Frech and Miller (1999 found that the OECD PPP exchange rates for both health care in general and pharmaceuticals in particular were consistent with those calculated by Danzon and Percy (1995) and Szuba (1986). As is illustrated in Table 3, these industry-specific PPF exchange rates tend to be very different from the GDP PPP exchange rates for most of the OECD countries included in our study.…”

“…This approach is only appropriate if prices for medical care goods and services differ across countries in the same way that prices differ in general. Researchers that have looked at this issue in depth, including Szuba (1986) and Danzon and Percy (1995), have demonstrated that this is far from the truth. Regulation of the medical care industry has remained a national prerogative in many countries and, in the case of pharmaceuticals, trade barriers have traditionally been significant.…”

The Determinants of Life Expectancy: An Analysis of the OECD Health Data

“…dollars using GDP PPP exchange rates underestimate actual pharmaceutical expenditures outside the United States. The drug-specific PPP exchange rates yield results that are consistent with those obtained using more accurate conversion factors developed by Szuba (1986) and others. Unfonunately.…”

Is the United States an outlier in health care and health outcomes? A preliminary analysis

“…Frech and Miller (1999 found that the OECD PPP exchange rates for both health care in general and pharmaceuticals in particular were consistent with those calculated by Danzon and Percy (1995) and Szuba (1986). As is illustrated in Table 3, these industry-specific PPF exchange rates tend to be very different from the GDP PPP exchange rates for most of the OECD countries included in our study.…”

“…This approach is only appropriate if prices for medical care goods and services differ across countries in the same way that prices differ in general. Researchers that have looked at this issue in depth, including Szuba (1986) and Danzon and Percy (1995), have demonstrated that this is far from the truth. Regulation of the medical care industry has remained a national prerogative in many countries and, in the case of pharmaceuticals, trade barriers have traditionally been significant.…”

The Determinants of Life Expectancy: An Analysis of the OECD Health Data

“…dollars using GDP PPP exchange rates underestimate actual pharmaceutical expenditures outside the United States. The drug-specific PPP exchange rates yield results that are consistent with those obtained using more accurate conversion factors developed by Szuba (1986) and others. Unfonunately.…”

Is the United States an outlier in health care and health outcomes? A preliminary analysis

“…Frech and Miller (1999 found that the OECD PPP exchange rates for both health care in general and pharmaceuticals in particular were consistent with those calculated by Danzon and Percy (1995) and Szuba (1986). As is illustrated in Table 3, these industry-specific PPF exchange rates tend to be very different from the GDP PPP exchange rates for most of the OECD countries included in our study.…”

“…This approach is only appropriate if prices for medical care goods and services differ across countries in the same way that prices differ in general. Researchers that have looked at this issue in depth, including Szuba (1986) and Danzon and Percy (1995), have demonstrated that this is far from the truth. Regulation of the medical care industry has remained a national prerogative in many countries and, in the case of pharmaceuticals, trade barriers have traditionally been significant.…”